Monday's top analyst upgrades and downgrades included Apple, BP, CrowdStrike, Delta Air Lines, Moody's, NuStar Energy, PPL, Salesforce.com, Slack Technologies and Wells Fargo.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Wednesday's top analyst upgrades and downgrades included AIG, CrowdStrike, Datadog, Devon Energy, eGain, Lyft, Moderna, Occidental Petroleum, Peloton Interactive and Yelp.
Two federal agencies have awarded AstraZeneca some $486 million to develop further the company's treatment and potential vaccine for COVID-19. The payment includes delivery of 100,000 doses of the medicine.
Paul Ausick President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug…
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and…
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing…
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many…
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says.…
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
